$0.16
+0.00 (+1.91%)
Open$0.15
Previous Close$0.15
Day High$0.16
Day Low$0.15
52W High$1.96
52W Low$0.15
Volume—
Avg Volume392.1K
Market Cap6.26M
P/E Ratio—
EPS$-3.93
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+14,158.1% upside
Current
$0.16
$0.16
Target
$22.10
$22.10
$15.13
$22.10 avg
$31.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.20M | 2.57M | 1.31M |
| Net Income | -348,468,255 | -366,980,376 | -292,011 |
| Profit Margin | -15,861.4% | -15,068.3% | -22.2% |
| EBITDA | -290,274,372 | -322,678,040 | -341,169 |
| Free Cash Flow | — | — | -173,511 |
| Rev Growth | -14.5% | -14.5% | +20.5% |
| Debt/Equity | — | — | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |